Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 7/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20189787 | 0.78 | DUT (0.61) | DUTMTNR1AALDH1A1NAMPTHTR1A | |
| SCHEMBL1409637 | 0.77 | DUT (0.65) | DUTALDH1A1NPSR1HTR1ADRD2 | |
| SCHEMBL27990764 | 0.76 | TLR4 (0.46) | DUTMTNR1ANAMPTACACBACACA | |
| SCHEMBL20189790 | 0.76 | DUT (0.61) | DUTALDH1A1HTR1ADRD2HTR7 | |
| SCHEMBL21690361 | 0.76 | DUT (0.64) | DUTMTNR1AALDH1A1HTR1ADRD2 | |
| SCHEMBL21522296 | 0.76 | DUT (0.58) | DUTALDH1A1NPSR1 | |
| SCHEMBL20188167 | 0.75 | DUT (0.57) | DUTMTNR1AALDH1A1NAMPTHTR1A | |
| SCHEMBL21536109 | 0.73 | DUT (0.46) | DUTMTNR1AKAT6A | |
| SCHEMBL21536107 | 0.73 | DUT (0.46) | DUTMTNR1AALDH1A1KAT6A | |
| SCHEMBL21536747 | 0.73 | DUT (0.54) | DUTMTNR1AALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168059-B2 | Amino sulfonyl compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-09 | — | — | US | disclosed |
| US-20190330158-A1 | AMINO SULFONYL COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| WO-2018098209-A1 | AMINO SULFONYL COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168059-B2 | Amino sulfonyl compounds | DPYD, DNPEP, DUT | DUT 3/4885MTNR1A 4500/4885ALDH1A1 2924/4885 |
| US-20190330158-A1 | AMINO SULFONYL COMPOUNDS | DPYD, DNPEP, DUT | DUT 3/4885MTNR1A 4500/4885ALDH1A1 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.